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1. ABSTRACT 
Bovine Leukemia virus (BLV) is the natural etiological agent of a lymphoproliferative disease in cattle. BLV can 
also be transmitted experimentally to a related ruminant species, sheep, in which the pathogenesis is more acute. 
Although both susceptible species develop a strong anti-viral immune response, the virus persists indefinitely 
throughout life, apparently at a transcriptionally silent stage, at least in a proportion of infected cells. Soon after 
infection, these humoral and cytotoxic activities very efficiently abolish the viral replicative cycle, permitting 
only mitotic expansion of provirus-carrying cells. Short term cultures of these infected cells initially indicated 
that viral expression protects against spontaneous apoptosis, suggesting that leukemia is a process of 
accumulation of long-lived cells. This conclusion was recently reconsidered following in vivo dynamic studies 
based on perfusions of nucleoside (bromodeoxyuridine) or fluorescent protein markers (CFSE). In sheep, the 
turnover rate of infected cells is increased, suggesting that a permanent clearance process is exerted by the 
immune system. Lymphocyte trafficking from and to the secondary lymphoid organs is a key component in the  
aintenance of cell homeostasis. The net outcome of the immune selective pressure is that only cells in which the 
virus is transcriptionally silenced survive and accumulate, ultimately leading to lymphocytosis. Activation of 
viral and/or cellular expression in this silent reservoir with deacetylase inhibitors causes the collapse of the 
proviral loads. In other words, modulation of viral expression appears to be curative in lymphocytic sheep, an 
approach that might also be efficient in patients infected with the related Human T-lymphotropic virus type 1. In 
summary, a dynamic interplay between BLV and the host immune response modulates a complex equilibrium 
between (i) viral expression driving (or) favoring proliferation and (ii) viral silencing preventing apoptosis. As 
conclusion, we propose a hypothetical model unifying all these mechanisms. 
 
2. INTRODUCTION 
Spleen enlargement and disruption leading to lethal hemorrhage are the most spectacular manifestations of BLV-
induced leukemia in cattle. In fact, the observation in 1871 of yellowish nodules in the enlarged spleen of a cow 
is considered to be the first reported case of bovine leukemia (1,2). These local proliferations of B cells, called 
lymphosarcoma or extranodal lymphoma, can infiltrate different tissues like the spleen, liver, heart, eye, skin and 
lungs. In addition, transformed B cells can also induce the enlargement of lymph nodes and cause lymphoma or 
lymphosarcoma (Figure 1). The development of these tumors within essential organs leads to a series of 
functional defects which are ultimately incompatible with survival. Another clinical manifestation associated 
with bovine leukemia, which is characterized by an increase in the number of peripheral blood B-lymphocytes, is 
called persistent lymphocytosis (PL). The PL stage, which affects approximately one third of the infected cattle 
is considered to be a benign form of leukemia (3). During this stage, the numbers of peripheral blood B cells can 
remain stable over extended periods of time without any other severe clinical sign. 
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The BLV retrovirus is transmitted horizontally through the transfer of infected cells, natural transmission 
occurring via direct contact, milk and possibly biting insects (4,5). However, iatrogenic procedures like 
dehorning, ear tattooing and essentially, the use of infected needles largely accounted for the propagation of the 
virus. Although it is widespread, BLV is still highly prevalent in several regions of the world (like in the US) but 
almost absent nowadays in others (in the EEC). In wilds, the natural reservoir of BLV could be the water buffalo 
(6). Experimentally, however, the host range of BLV has been extensively studied in different animal species. 
Successful transmissions of BLV have been described for a number of species including rabbits, rats, goats and 
sheep (7-10). In contrast, humans do not seem to be susceptible to BLV, although cell lines can be infected in 
vitro and although there is some antigenic cross-reactivity between two related viral proteins (p24gag) of BLV 
and HTLV (Human T-lymphotropic virus type 1) (11,12). In addition, epidemiological studies have shown that 
consumption of raw milk from infected cattle did not lead to an increase in leukemia in man (13). Therefore, it is 
unlikely that BLV infects, replicates or induces cancer in humans. 
Like HTLV-1, BLV belongs to the deltaretrovirus genus. Sequence variations among different BLV isolates are 
very limited (14). Its genome contains the classical structural genes (gag, pol and env) coding, respectively, for 
the viral capsid, the RNA-dependent DNA polymerase (the reverse transcriptase) and the envelope (Figure 2). A 
series of other open reading frames at the 3'-end of the genome encode regulatory proteins: Tax, Rex, R3 and G4 
(15-22). Tax and Rex are essential proteins required for transcriptional and post-transcriptional activation of viral 
expression. The R3 and G4 proteins are dispensable for infectivity but are involved in the maintenance of high 
viral loads (23-25). G4 harbors oncogenic potential and interacts with farnesyl pyrophosphate synthetase, an 
enzyme involved in prenylation of Ras. Further details on BLV genome structure, gene functions and genetic 
determinants are available in a series of reviews (26,27). 
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3. ONE PATHOGEN IN TWO DIFFERENT HOSTS DEVELOPING RELATED DISEASES 
Amongst different animal species susceptible to experimental infection by BLV, only sheep and to a lesser 
extent, goats develop leukemia / lymphoma (28). Interestingly, the latency period before the onset of the disease 
is shorter in sheep than in cattle: leukemia occurs usually 1 to 4 years after infection (instead of 4 to 10 years in 
cows). In addition, the frequency of viral-induced pathology is much higher: almost all the infected sheep will 
succumb within their normal life time compared to about 5 per cent in cattle (2,29). There are many similarities 
but also marked differences between the diseases induced in cattle and in sheep. One of the main difference 
concerns the kinetics of the proviral loads. In cattle, most of the infected animals remain clinically healthy, the 
numbers of infected cells ranging around 1 per cent or less. A fraction of these infected animals will develop a 
persistent lymphocytosis during which the proviral loads remain relatively constant over extended periods of 
time. In sheep, the number of infected cells in the peripheral blood rise more gradually until the onset of 
leukemia (levels of circulating lymphocytes being above 10,000 per mm3 and up to 500,000 per mm3) (27,30), 
although lymphocytosis can last for several months. It should be mentioned that persistent lymphocytosis in 
cattle or leukemia in sheep are not mandatory steps preceding the acute phase. Indeed, in a significant number of 
cases, leukemia/lymphoma/lymphosarcoma can develop within the animals in the absence of any lymphocyte 
accumulation in the peripheral blood. However, the probability of tumor development being greater in animals 




Figure 2. Schematic representation of the BLV and HTLV-1 genomic structures. Three structural genes code for the viral 
capsid (gag), the reverse transcriptase / integrase (pol) and the envelope (env). A series of other open reading frames (ORFs) at the 3'-end of 
the genome encode regulatory proteins: Tax, Rex, R3 and G4 (BLV) or pl2 and pl3/p30 (HTLV). These ORFs are translated from complex 
single or multiple spliced mRNAs (see 15,26,90 for further details). Tax and Rex are essential proteins required for transcriptional and post-
transcriptional activation of viral expression. The R3 and G4 proteins are dispensable for infectivity but are involved in the maintenance of 
high viral loads. 
 
 
Another difference between the pathologies associated with BLV in cattle and in sheep concerns the genetic 
modifications that occur during the leukemogenic process. In this context, a major regulator involved in the 
defense mechanisms against cell transformation, is the p53 tumor suppressor gene. In vitro, the establishment of 
immortal cell lines appears to be associated with frequent alterations of p53. In vivo, approximately half of the 
solid tumors induced by BLV in cattle contain a mutated p53 gene (31,32). These mutations interfere with 
essential p53 functions required for transactivation and suppression of cell growth (33). In contrast, very few 
mutations were found in B cells from cows with PL and none of the uninfected cattle tested harbored a mutated 
p53 tumor suppressor gene. Since p53 was never found to be mutated at any stage of the disease in sheep, one 
might speculate that p53 mutations in cattle favor cell transformation and significantly extends the latency period 
preceding onset of leukemia/lymphoma as well as the relatively low levels of solid tumor development. 
Together, these observations illustrate a difference in the pathogeneses induced by BLV in a natural (cattle) and 
an experimental host (sheep), disease acuteness being more pronounced in the latter, as expected. Throughout 
evolution, the relationship between a pathogen and its natural host frequently evolve towards lack of 
pathogenicity, which represents the ultimate symbiosis (34,35). 
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4. STRONG BUT APPARENTLY INEFFICIENT HUMORAL AND CYTOTOXIC IMMUNE 
RESPONSES 
Natural or iatrogenic transmission of BLV thus primarily involves the transfer of infected cells via blood or milk 
(5). The processes occurring after this primary infection still remain obscure. One of the earliest indications of 
infection is the onset of a humoral antiviral response at about 1-8 weeks post-inoculation (36,37). Antibodies 
recognizing epitopes from structural (envelope gp51 and capsid p24) and regulatory proteins (Tax and Rex) are 
synthesized at high titers. Some of these antibodies are directly lytic for BLV-producing cells (38). Almost 
concomitantly to the early seroconversion period, cytotoxic T-lymphocytes (CTL) specific for Tax and Envelope 
epitopes appear in the peripheral blood (39,40). Compared to humans, a peculiarity of cattle is that gammadelta 
T-lymphocytes are major players in this cytotoxic response (41). BLV infection also triggers both a virus-
dependent and a virus-independent CD4 helper T cell response (42-44). The susceptibility to the polyclonal 
expansion of BLV-infected B lymphocytes is associated with specific alleles of the major histocompatibility 
complex system (45,46). Importantly, viral infection correlates with overexpression of two key Th-1 cytokines: 
TNF-alpha (47-49) and interferon-gamma (50). Finally, the interleukin network is profoundly deregulated at 
different stages of the disease in particular IL-2, -4, -6, -10 and -12 (47,51-55) but the precise role of these 
cytokines during pathogenesis still remains unclear. 
It thus appears that a very active humoral and cytotoxic immune response is induced soon after BLV infection. 
Importantly, these anti-viral activities amplify and persist throughout the animal's life indicating that the immune 
system is permanently stimulated by BLV antigens. Indeed, the level of antibody-mediated cytolytic activity 
increases with progression of the disease towards the acute phase (38). A strong CTL response is relatively 
unexpected for a chronic infection, at least if associated with a latent virus (see # 5 and 8 for comments on this 
assumption). Presently, there is no clear evidence for inhibition mechanisms that would impair virus clearance 
from the infected host such as, for example, downregulation of MHC class I molecules preventing CTL 
recognition (reviewed in 56). 
 
5. IS THE VIRUS TRANSCRIPTIONALLY SILENT? THE CAVEATS OF A DOGMA 
This question has long been, and still is, a matter of extensive debate. Many experimental arguments support a 
lack of expression in detectable (i.e. viable) cells harboring an integrated provirus. First, BLV virions or viral 
proteins cannot be directly detected in the peripheral blood by any available technique (ELISA, flow cytometry, 
immunoprecipitation or Western blotting). Second, viral transcripts from peripheral blood lymphocytes or 
tumors can only be amplified by means of very sensitive RT-PCR techniques (15,57,58). Third, using flow 
cytometry cell sorting and subsequent RT-PCR, only about one B lymphocyte out of 10,000 is found to express 
tax/rex mRNA during persistent lymphocytosis (57). Fourth, only rare cells in the peripheral blood (1 in 50,000) 
contain enough BLV transcripts to be identified readily by in situ hybridization (59,60). However, upon ex vivo 
short term culture, transcription is activated by components of fetal bovine serum and can be augmented by 
molecules that mimic activation of immune cells. 
All these observations are thus in favor of a model postulating that the virus is latent in the very large majority of 
detectable cells. More, plasma from infected animals contains a fibronectin-related protein that inhibits BLV 
expression in peripheral blood mononuclear cell cultures (61,62). The latency of BLV in vivo and its reactivation 
upon ex vivo culture thus became a long-lived dogma. There are however a series of caveats in this model. 
Indeed, as mentioned in the previous paragraph, the maintenance of a vigorous anti-viral immune response in 
infected animals indicates that some degree of virus expression must occur in vivo. Furthermore, BLV 
transcription can even be detected in samples of whole blood upon incubation at 37°C without addition of any 
exogenous factor except anticoagulants (63). Then, why would this process not be ongoing permanently in 
infected cells in vivo? If anticoagulants do not activate viral expression, it is unlikely, although not impossible, 
that the simple removal of blood would be sufficient to induce BLV transcription. Alternatively, we favor the 
idea that viral expression occurs permanently in a subpopulation of infected cells, which are very efficiently 
killed by the immune system. The cytotoxic and humoral responses are however unable to destroy cells in which 
viral transcription is completely silenced. 
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6. HOW DOES THE VIRUS REPLICATE? VIRAL REPLICATION CYCLE AND CELLULAR 
CLONAL EXPANSION 
Morphologically, the BLV virion has a diameter ranging between 60 and 125 nanometers, and contains a central 
electron dense nucleoid surrounded by an outer envelope. Its genome is constituted by two poly-A ribonucleic 
acid molecules bound to viral nucleocapsid proteins (27). This complex is surrounded by a capsid linked to the 
outer envelope by matrix proteins. The envelope is formed by a cellular lipid bilayer in which two viral proteins 
(the transmembrane gp30 and the extracellular gp51) are embedded. After infection of a target cell, the RNA 
genome is copied into DNA by the virally-encoded reverse transcriptase. The so-formed provirus then randomly 
integrates into the host genomic DNA by means of the viral integrase. As mentioned previously, this integrated 
provirus is by far the most commonly detectable viral form observed in persistently infected animals. 
Theoretically, viral spread occurs via the replicative cycle after expression of virions able to infected novel target 
cells. Alternatively, the integrated proviruses can expand by mitosis of the host cell by a process referred to as 
clonal expansion (64). Semiquantitative inverse PCR amplification of the cellular sequences flanking the BLV 
provirus has revealed that the viral load results almost exclusively from clonal expansion of infected cells (30). 
Importantly, the premalignant cellular clones from which the tumor originates can be detected as early as a few 
weeks after experimental infection. In fact, the latency period preceding onset of leukemia/lymphoma is 
characterized by a fluctuation in the abundance of different cellular clones harboring an integrated provirus. 
Malignancy of a given clone correlates with the accumulation of somatic mutations revealing a decrease in the 
genetic stability of the expanding infected cell. During the asymptomatic phase, most of the proviral load is 
sustained by mitosis of the infected cell (Figure 3). Efficient virus replication via the expression of virions and 
infection of new target cells seems to occur mostly, if not almost exclusively, during a very short period 
following viral inoculation (so-called primary infection). It is still however possible that the replicative cycle is 
ongoing continuously but the net outcome of this process does not contribute significantly to the observed viral 
load, very likely due to a very efficient immune response. 
Two key and related questions remain to be solved: why is the abundance of the infected cell clones fluctuating? 
And: what is the driving force of the clonal expansion process? Based on the extensively described oncogenic 
properties of Tax (26,65-67), our tenet is that this virally encoded protein triggers cell proliferation. However, 
the selective growth advantage of the infected cells could also possibly be provided by a non-peptidic viral 
factor, such as for instance microRNAs (68). 
 
7. DOES THE VIRUS PROTECT FROM APOPTOSIS? THE MOST STRAIGHTFORWARD AND 
THE ALTERNATIVE INTERPRETATIONS 
Apoptosis is an active program leading to the destruction of cells in which abnormalities have occurred, for 
example, those infected by viruses or triggered by oncogenes. In principle, inhibition of this process alters the 
equilibrium between proliferation and cell death, modifies homeostasis within an organism and can ultimately 
lead to leukemia. In other words, apoptosis appears to be an essential mechanism required for the elimination of 
pre-transformed or normal infected cells and, it is not surprising that viruses have developed strategies to inhibit 
this process (56). 
A key and apparently conclusive experiment is illustrated on Figure 4. When lymphocytes are isolated from a 
BLV-infected sheep and maintained for a few hours in culture, almost all cells expressing the major viral capsid 
protein p24gag (used as a marker for viral expression) are not stained by terminal transferase-mediated DNA end 
labeling (TUNEL). The most straightforward interpretation is that viral expression correlates with protection 
against spontaneous apoptosis. This observation fits well with previous reports showing that B-lymphocytes 
from infected sheep are less prone to undergo apoptosis compared to the controls (69,70). However, an 
alternative interpretation is that cells that spontaneously express p24gag antigen are cleared in vivo and can 
therefore not be detected ex vivo. If so, the low but significant percentages of p24+TUNEL+ double positive 
cells represent those having escaped immune destruction. Spontaneous viral expression observed ex vivo could 
occur at similar rates in vivo but would be hidden by the immune surveillance. 
The major problem of these ex vivo experiments is that it is never possible to perfectly reproduce the situation 
prevaling in vivo. Even under the culture conditions that most closely reproduce the natural milieu (such as 
culture of heparin-containing blood), interpretations of data will always face experimental objections. 
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Figure 3. Two modes of viral propagation via the replicative cycle and the clonal expansion of the infected cell. 
Although both mechanisms likely co-exist throughout all stages of infection, the net contribution of the viral replicative cycle during the 





Figure 4. Dot plot resulting from a flow cytometry analysis of peripheral blood mononuclear cells isolated from 
a lymphocytic BLV-infected sheep and transiently cultivated during 24 hours. Cells were labeled with a monoclonal 
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8. CELL DYNAMICS OF PATHOGENESIS IN DIFFERENT MODELS 
To further gain insight into the processes mediating pathogenesis, it became interesting to define the kinetic 
parameters sustaining the dynamics of the different cell populations in the infected animals. Indeed, as indicated 
in the previous paragraph, lymphocyte homeostasis is the result of a critical balance between cell proliferation 
and death. Disruption of this equilibrium can lead to the onset of leukemia, an increase in the number of 
lymphocytes being potentially due to one or both of these parameters. The proliferation rates in BLV-infected 
and healthy sheep have first been determined via a method based on intravenous injection of bromodeoxyuridine 
(BrdU). By this in vivo approach, B-lymphocytes in BLV-positive asymptomatic sheep were shown to 
proliferate significantly faster than in uninfected controls (average proliferation rate of 0.020 day-1 versus 0.011 
day-1), meaning that an excess of 0.9 % cells (the difference between 2 and 1.1 %) are produced by proliferation 
each day (71). The difference in the proliferation rates becomes even more evident at the terminal neoplastic 
stage of the disease (proliferation rate increased by up to tenfold). Cells in S/G2M then also appear in the 
peripheral blood (our unpublished results) as has been documented for acute cases of human non-viral leukemia 
(72). In contrast, the death rates of the BrdU-positive cells are not significantly different between aleukemic 
BLV-infected and control sheep (average death rate 0.089 day-1 versus 0.094 day-1, respectively). 
In the natural host, BLV-infected cattle, the cell proliferation rates in asymptomatic and control animals are not 
significantly different (73). Surprisingly, the PL stage is characterized by a decreased B cell turnover resulting 
from a reduction of cell death as well as from an overall impairment of proliferation. Paradoxically, an excess of 
B lymphocytes in the peripheral blood in PL animals correlates with a reduction of cell proliferation, suggesting 
that a mechanism of feedback regulation controls lymphocyte homeostasis. The reduced dynamic parameters 
measured in cattle thus contrast with the kinetics observed in experimentally infected sheep. Whether these 
observations relate to the differences in disease acuteness in the two host species remains a tempting but still 
open assumption. 
As mentioned in section 5, cells expressing viral proteins cannot be directly observed in the peripheral blood of 
the infected animals at any stage of the disease. However, viral expression can be induced upon transient short 
term culture. Surprisingly, very few (if any) cells spontaneously synthesizing p24gag antigen undergo 
proliferation in vivo (71,73). Indeed, dual flow cytometry labeling demonstrates an almost complete absence of 
p24+BrdU+ double positive cells, revealing the mutually exclusive presence of both markers. In other words, 
amongst all infected cells proliferating in vivo as measured by BrdU uptake, none of them are found to express 
viral proteins. Since lymphocytes synthesizing p24gag are spared from apoptosis ex vivo (see #7), p24+BrdU+ 
double positive cells are not lost during the culture but have rather been eliminated in vivo (Figure 5). If we 
postulate that viral expression and cell activation are closely linked, as widely illustrated in the literature, the 
lack of p24+BrdU+ double positive cells reveals a very efficient negative selection taking place in vivo. Another 
non-exclusive interpretation would be that only a subpopulation of infected cells is allowed to proliferate (i.e. 
incorporate BrdU) providing that no viral proteins are expressed. However, this model does not fit with the 
progressive accumulation of provirus-positive cells, if proliferation is triggered by a viral protein. What would 
indeed be the selective advantage of a cell carrying a completely silent provirus? Whatever the underlining 
mechanism, these kinetic studies cast light onto a very active process of immune selection directed towards 
proliferating infected cells that express the harbored provirus. 
 
9. LYMPHOCYTE TRAFFICKING IN LYMPHOID ORGANS 
Homeostatic regulation of lymphocyte numbers in the peripheral blood results from a series of physiological 
factors, of which cell proliferation and death are only partial components. Indeed, kinetics of a cell population is 
also influenced by recirculation to lymphoid organs, in which proliferation is thought to primarily occur, at least 
under normal conditions. Experiments based on BrdU kinetics thus pertain mainly to cells in lymphoid tissues 
leading to an apparent discrepancy: the imbalance created by the net increase in proliferation in the absence of 
compensating cell death is estimated at 7 % growth in a day (71). Since this considerable growth rate is not 
reflected by an increase in the corresponding lymphocyte numbers, other regulatory mechanisms including a 
reduction of recirculation through the lymph nodes as well as a massive elimination of cells in other tissues 
could play a role. To test these hypotheses, B cell migration from blood to lymph and back from lymph to blood 
has been traced with the carboxyfluorescein diacetate succinimidyl ester (CFSE), a fluorescent dye that labels 
proteins via their NH2 terminal ends. Direct intravenous administration of CFSE into sheep achieves remarkable 
labeling indexes: more than 98% of peripheral blood leukocytes become fluorescent within seconds (74). Since 
CFSE is extremely unstable in aqueous solution, labeling is very short lived, making it feasible to track 
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lymphocyte migration from the periphery through the lymph node in vivo. While most studies of lymphocyte 
recirculation and homing have been done in rodents, the sheep model offers the opportunity to study the 
recirculation of lymphocytes through tissues by direct cannulation of individual lymphatic vessels (75-77). Using 
this approach, it has however been shown that B-lymphocytes from BLV-infected and control sheep recirculate 
with similar rates (Debacq et al, submitted). In contrast, the proportions of labeled B cells in the peripheral blood 
decrease significantly faster in infected sheep (Figure 6A). Combined with another parameter (the halving of the 
fluorescent dye upon cell division), it is further possible to calculate the proliferation and death rates (78) (Figure 
6B). These calculations indicate that B cells labeled with CFSE in the peripheral blood undergo massive 
destruction during BLV chronic infection of sheep (Debacq et al, submitted). 
Collectively, quantification of the dynamic parameters deduced from BrdU and CFSE kinetics shows that the 
excess of proliferation in lymphoid organs can be compensated by increased cell death (Figure 7). An important 
issue that remains to be clarified is to identify the anatomic site required for this cell destruction. In this context, 
our ongoing experiments reveal that the spleen is a major lymphoid tissue regulating infected cell dynamics and 
perhaps pathogenesis. 
 
Figure 5. Schematic representation of BrdU incorporation in vivo (hypothetical) and p24gag labeling after short-
term culture (ex vivo). The uninfected cell is hachured whereas black squares and full circles indicate BrdU and p24 markers, 
respectively. The crosses mean that the cells were undetectable by flow cytometry because they did not exist ore more likely because they 
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Figure 6. In vivo CFSE kinetics. A. The CFSE fluorescent dye was injected intravenously into the jugular vein of 
BLV-infected (red) and control sheep (green). Blood was collected at different time intervals (days on the X axis) and the 
proportions of CFSE-positive B lymphocytes (Y axis) were determined by flow cytometry. At day 0, more than 98% of peripheral blood B 
lymphocytes are labeled with CFSE. The percentages of CFSE-positive B cells decrease faster in BLV-infected sheep. B. Since CFSE labels 
proteins via their NH2 terminal ends, it is assumed that halving of the fluorescent dye occurs upon cell division. The combination of these 




Figure 7. Summary of dynamic data resulting from in vivo BrdU and CFSE kinetic experiments. Quantification of 
the dynamic parameters determined from the BrdU and CFSE kinetics shows that the excess of proliferation in lymphoid organs can be 
compensated by increased cell death of the peripheral blood compartment, thereby maintaining homeostasis. 
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10. MODULATION OF VIRAL EXPRESSION AS THERAPY 
In the absence of ex vivo cell culture, the infected lymphocytes apparently do not express any viral protein in the 
peripheral blood and rest in the G0/G1 phase of the cell cycle (section 5). These apparently quiescent cells may 
undergo spontaneous cell proliferation and express virions upon transient short-term culture (section 7). Agents 
known to activate immune cells polyclonally cause an increase in the number of cells containing BLV RNA 
(59). Viral expression may thus be induced by activation of the host cell consecutively to immune-mediated 
stimulation. 
It is possible that an inhibitory mechanism (or the absence of a driving force: see section 11) hampers viral gene 
expression in vivo. Infected cell persistence would thus be permitted under the restrictive condition that the virus 
is not expressed (or at least at a level undetectable by the immune system). Evidence for a very strong immune 
response is supported by the presence of virus specific cytotoxic T cells and by high titers of cytolytic antibodies 
(section 4). However, the lack of viral expression in a large proportion of infected cells does not allow efficient 
clearance by the immune system. Concomitantly, virus infection might also correlate with inhibition of the 
apoptotic processes, generating a reservoir of apparently latent cells (section 6). In this context, we aimed at 
evaluating the therapeutic effectiveness of a strategy based on the induction of viral and cellular gene expression. 
Among a number of methodological approaches, modulation of chromatin condensation, which is an essential 
component of the gene expression pattern, can be achieved by interference with the level of histone acetylation 
(79). This process results from an intrinsic balance between the activity of two families of antagonistic enzymes, 
histone deacetylases (HDAC) and histone acetyltransferases, respectively removing or incorporating acetyl 
groups into core histones. Although this model is probably oversimplified, acetyl removal by HDACs restores a 
positive charge to the lysine residues in the histone N-terminal tails and is thought to increase the affinity of 
histones for DNA, leading to transcriptional repression. Conversely, impairment of HDAC function with specific 
HDAC inhibitors activates both cellular and viral gene transcription. 
Among a growing list of HDAC inhibitors, valproate (the sodium salt of 2-propylpentanoic acid) offers a series 
of advantages (80). Widely used for several decades for the treatment of epilepsy, this short-chain fatty acid has 
a very high bioavailability, exhibits very low toxicity in adults and, with a half life of 16-17 hours, has suitable 
pharmacokinetic properties in vivo. Therefore, valproate has been selected to evaluate the effectiveness of a gene 
activation chemotherapy in leukemic sheep. Indeed, valproate effectively activates BLV gene expression in 
transient transfection experiments and in short-term cultures of primary B-lymphocytes (81). In vivo, valproate 
administration, in the absence of any other cytotoxic drug, is efficient for the treatment of leukemia/lymphoma in 
sheep, demonstrating the proof-of-concept of a therapy that targets the expression of viral and/or cellular genes. 
Interestingly, over a long term period, valproate treatment alters neither the cell numbers in control sheep nor 
other lymphocyte populations in BLV-infected animals, revealing a relative innocuousness of the therapy. 
The mechanism by which valproate specifically decreases the number of leukemic cells remains to be 
determined. Amongst numerous hypotheses, we favor a model based on transient activation of cellular and/or 
viral expression leading to apoptosis by intrinsic (for instance dependent on mitochondrial regulated 
checkpoints) or extrinsic mechanisms related to membrane-bound receptors (Fas, TRAIL,...) (82-84). 
Alternatively, a very attractive model would include the induction of viral expression and destruction by the 
cytotoxic and humoral immune responses (85). 
We propose that the concept of a therapy that targets the expression of viral and cellular genes might be a 
promising treatment of adult T cell leukemia (ATL) or human T-lymphotropic virus-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP), diseases for which no satisfactory treatment exists so far. 
 
11. A TENTATIVE UNIFYING MODEL AS CONCLUSION 
If the latter model described in the previous section is valid, the efficiency of the valproate therapy thus indicates 
that it is possible to deplete BLV-infected cells via the immune response providing that viral proteins are 
expressed. In this context, repression of viral expression is a key element during pathogenesis. Indeed, the BLV 
transcriptional promoter located in the 5' long terminal repeat contains suboptimal binding sequences for the 
CREB transcription factor. Remarkably, the cyclic-AMP responsive site (CRE) consensus "TGACGTCA" is 
never strictly conserved in any viral strain and always contains a mutation (for example, AGACGTCA, 
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TGACGGCA, TGACCTCA). Restoring a perfect CRE sequence into the promoter increases LTR (long terminal 
repeat) promoter activity, as expected (86). Very surprisingly however, the proviral loads are drastically reduced 
in sheep infected with a virus harboring this type of mutation. It is tempting to speculate about a hiding process 
allowing the virus to maintain its promoter silenced while CRE-dependent pathways activate cellular promoters 
harboring perfect fits of CRE enhancer sequences. Together, these observations thus show that repression of 
viral expression is a key factor of viral persistence and spread. 
BrdU kinetics and recirculation studies (sections 8 and 9) have demonstrated that proliferation is accelerated in 
infected sheep and that homeostasis is maintained by increased death of the peripheral blood cell population. 
Amongst a series of plausible hypotheses that cannot be formally excluded, one of the possible models is that the 
increased turnover results from an activated immune response directed towards the virus. Continuous expression 
of viral antigens could indeed exacerbate proliferation of virus-reactive immune cells either directly or via 
cytokines and potentially also expansion of BLV-infected B lymphocytes. Excessive proliferation of uninfected 
B-lymphocytes in response to BLV early infection has recently been clearly documented (87). In addition, 
uninfected B lymphocytes also accumulate above normal levels during persistent lymphocytosis. Whether a 
similar anti-viral process is also responsible for expansion of BLV-infected B cells is presently unknown. It 
would for instance be interesting to determine the IgM specificity of the infected B lymphocytes. Arguments 
against this hypothetical mechanism of indirect viral spread include the absence of selective growth advantage 
conferred to the infected cells. Why would a viral antigen-specific B cell be preferentially infected by the virus? 
We therefore favor a model in which the virus plays an active role by continuously expressing viral proteins, like 
the Tax oncogene, able to promote cell proliferation and transformation (26,49,65-67). Tax expression could be 
permanent providing that cells escape from immune response, which is a rare event, or initiated indirectly via 
cellular activation. Concomitantly, Tax expression would also stimulate the anti-viral immune response, which 
in turn would clear the infected cells. Shutoff of viral expression possibly by a viral accessory protein (and/or 
histone modification, see section 10) would be a prerequisite allowing a minority of these cells to escape from 
immune response. Alternatively, since the presence of the doubly spliced tax/rex transcript in the cytoplasm 
precedes that of other viral mRNAs (88), it is possible that a subpopulation of cells would exclusively express 
the Tax protein at least during a short time interval. Since very few lymphocytes expressing viral proteins can 
directly be observed in vivo (section 5), the frequency of infected cells surviving the host immune pressure is 
low. Also, this process would only marginally affect the very large majority of infected cells containing a silent 
virus (or a less frequently expressed virus). The net outcome of this model would be a global stability of the 
proviral loads with some fluctuations of individual clones, as revealed by long term follow up of proviral 
integration sites by ligation-mediated PCR (section 6). Although the mechanism is still unknown, variations in 
the abundance of provirus-positive cell clones could be due to differential antigen stimulation or to modulation 
of the proportions of individual progeny cells to express virus. Hence, cells isolated from sheep at terminal 
stages of the disease loose their ability to efficiently express virus ex vivo even in the presence of potent 
polyclonal activators such as phorbol esters (our unpublished results). Ultimately, a fully transformed cell clone 
containing a deleted replication defective provirus can even outgrow and induce leukemia (89). 
To conclude, the hypothetical model illustrated on Figure 8 best reconciles all current experimental evidences: 
the oncogenic potential of Tax, the permanent stimulation of the immune system, the low levels of detectable 
cells expressing viral proteins in vivo, the apparent stability of individual proviral clones and the dynamic 
parameters. During BLV chronic infection, the host-pathogen interplay is thus characterized by a very dynamic 
kinetics generating an equilibrium between a virus attempting to proliferate under a tight control exerted by the 
immune response. In this model, the virus thus permanently transits between a latent and transcriptionally active 
phase resulting in the progressive accumulation of viable infected cells. Occurrence of somatic mutations 
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Figure 8. Tentative unifying model conciliating immunological and molecular genetics data. Agents known to 
activate immune cells polyclonally cause an increase in the number of cells containing BLV RNA. Viral expression may thus be induced by 
activation of the host cell consecutively to immune-mediated stimulation. The selective growth advantage of BLV-infected cells is very 
likely provided by a virally encoded factor, probably Tax or G4. Indirectly, Tax expression also stimulates the expression of structural genes 
leading to the destruction of the infected cells by the anti-viral host immune response. Shutoff of viral expression possibly by viral accessory 
proteins then allows a minority of these cells to escape from immune response. Since very few lymphocytes expressing viral proteins can 
directly be observed in vivo, the frequency of infected cells surviving the host immune pressure is low. Also, this process would only 
marginally affect the very large majority of infected cells containing a silent provirus, accounting for the relative stability of the proviral 
clones. Valproate treatment would activate a proportion of cells containing a silent provirus which, upon expression of viral proteins, are 
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